|摘要||目的 探讨护肝宁片对大鼠非酒精性脂肪性肝炎的治疗作用及机制.方法 雄性SD大鼠39只,正常喂养1周后按体质量层次随机分为正常对照组(n=9)和实验组(n=30),正常对照组予标准饮食,实验组予高脂饮食.11周末验证造模成功后,将余下25只实验组大鼠再分为:高脂组、饮食治疗组,及护肝宁高剂量组、中剂量组、低剂量组.分别给予高剂量、中剂量、低剂量护肝宁片灌胃及标准饮食.16周末处死大鼠,检测肝指数、体脂比、血清ALT、AST、TC、TG、LDL-C、血糖、超氧化物歧化酶(SOD)、丙二醛,并行肝组织病理检查及肝匀浆TC,TG,LDL-C和丙二醛测定.结果 护肝宁中剂量组、护肝宁低剂量组体脂比[分别为(3.08±0.49)%与(3.07±0.82)%]较饮食治疗组及高脂组降低(P<0.05);护肝宁高剂量组血清AST水平、TC水平、血糖水平及肝匀浆TC水平[分别为(119.8±14.7)U/L、(1.59±0.38)mmol/L、(5.44±0.44)mmol/L及(0.34±0.07)mmol/L]明显低于饮食治疗组,护肝宁高剂量组血清SOD水平[(47.38±5.72)%]明显高于饮食治疗组(P<0.05);护肝宁高剂量组较饮食治疗组及高脂组肝组织的脂肪变程度、炎症程度和纤维化程度均明显减轻(JP<0.05).结论 护肝宁片可有效治疗大鼠非酒精性脂肪性肝炎.
Objective To investigate the protective effect and mechanism of Huganning tablet on rat model of nonalcoholic steatohepatitis( NASH). Methods After one week of a standard diet 39 male SD rats were random-ly divided into the normal control group(n =9) and the experimental group(n =30). The normal control group rats were fed with a standard diet, while those of the experimental group had a high-fat diet. After 10 weeks 9 rats were sacrificed to verify whether the model was established successfully. Then the experimental group was randomly sub-divided into five groups :Group Z(n =5) with a high-fat diet and gastric with saline, GroupY(n=5) with a stand-ard diet and gastric with saline, GroupA(n=5), Group B(n=5) and Group C(n =5) with a standard diet and gastrically infused with the Huganning Tablet solution of high-dosage (700 mg/kg/d), middle-dosage (350 mg/kg/d) and low-dosage(175 mg/kg/d), respectively. Four weeks later, all rats were sacrificed. Blood samples were collected to measure serum ALT, AST,TG,TC, LDL-C, GLU, SOD and MDA. Tissue samples were duly taken for histopathological examination and measurement of tissue TC, TG, LDL-C and MDA levels. Results There were lower levels of visceral adiposity ratio in Group B and Group C compared with Group Y( P <0. 05 ). There were low-er levels of serum AST, TC, GLU and liver tissue TC in Group A compared to Group Y(P<0.05). A significant increase was found in the serum SOD levels in Group A compared to Group Y( P < 0. 05). A significant reduction was observed in Group A in the hepatic steatosis, the grade of inflammation and the stage of fibrosis compared to Group Y and Group Z ( P < 0. 05). Conclusions Huganning Tablet seems to be effective in attenuating hepatic damage in the NASH model induced by a high-fat diet, which may become a potential drug for NASH treatment in the future.|